# The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

> **NCT06109558** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hunan Province Tumor Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- RET Gene Mutation
- MET Amplification
- EGF-R Positive Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** LMV-12(HE003)

## Key facts

- **NCT ID:** NCT06109558
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-31
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06109558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06109558, "The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06109558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*